Cold Storage Stock Claims for Malaysia Pharma Factories

Cold storage stock claims in Malaysian pharma factories hinge on the cause of loss: machinery breakdown of refrigeration equipment routes to a Machinery Breakdown claim, off-premises power failure for more than the policy waiting period routes to Deterioration of Stock, and in-transit cold-chain breaches route to Marine Cargo or Goods in Transit. The cover that pays is decided by the cause, not by the spoiled product. The pharma layer on top of this routing logic is GDP, PIC/S, and NPRA: the product is regulated, the documentation trail is regulated, and the corrective action expected after an excursion is regulated.

That scene unfolds somewhere in Malaysia more often than the industry acknowledges. What happens next, in insurance terms, is the subject of this article. Cold storage stock claims for pharma factories sit on the same routing logic as the F&B claim scenarios Foundation covers in cold storage stock claims for F&B factories, but the regulatory overlay is heavier. The cover routing depends on what caused the temperature failure, not on the fact of the failure itself. A bearing seizure in the compressor goes to one policy. A power failure originating outside the building goes to another. A cold-chain breach during transit goes to a third. The scenarios below walk the routing in plain language and flag the pharma-specific compliance steps that run in parallel with the claim itself.

Why the Cause of the Failure Drives the Cover Routing

Stock that has fallen outside its validated temperature range looks the same regardless of cause. But Malaysian pharma cold-chain cover is typically structured across two or three policies:

• Deterioration of Stock cover, usually written as an extension on the property or pharmaceutical factory insurance policy, or under a dedicated cold storage stock wording. Responds to temperature excursion caused by an insured peril (typically power failure or machinery breakdown affecting the refrigeration plant).
• Machinery Breakdown on the refrigeration plant itself. Responds to sudden and accidental mechanical or electrical breakdown of the refrigeration equipment.
• Marine Cargo / Goods in Transit for stock that is in motion between sites. Responds during transport, with its own conditions and warranties on temperature control and data logging.

The first claim question is not "did the stock fall outside spec?" but "what was the proximate cause of the temperature failure?" The answer routes the claim to the right policy. Background on the broader cold chain product set is in Foundation's cold storage and cold chain insurance coverage guide, and a more detailed view of the deterioration of stock wording itself is in deterioration of stock insurance for cold storage and frozen goods. The pharma overlay (good distribution practice expectations, PIC/S alignment, NPRA reporting, and the corrective and preventive action framework) sits alongside the insurance routing rather than replacing it.

Scenario 1: Vaccine Cold Store Compressor Failure Overnight

What Actually Happens

The compressor bearing fails. The compressor stops. The chamber temperature rises. Validated stock crosses the upper end of its labelled storage range within roughly two hours. Some products tolerate brief excursions above 8 degrees under their manufacturer's stability data; many do not. The quality assurance team applies the facility's GDP temperature excursion procedure: stock is quarantined, the manufacturer is contacted for a stability assessment where the product allows, and any product where the excursion exceeds the manufacturer's permitted limit is segregated for destruction. Depending on the product class and the facility's NPRA-registered procedures, a report to the regulator may follow.

What the Deterioration of Stock Cover Pays

Most PIAM-aligned deterioration of stock wordings respond when the cause is an insured peril, including machinery breakdown of the refrigeration plant. Where the policy is endorsed for pharma cold-chain risk, the cover pays the value of stock that fails the stability assessment and must be discarded, subject to:

• The cover sub-limit and excess on the deterioration of stock extension.
• The basis of valuation in the wording (cost, wholesale price, or other defined basis).
• The sum insured being adequate (under-declaration triggers the average clause).
• The pharma-specific clauses if the wording carries any (GDP compliance warranty, validated cold-chain warranty, data logger requirements).

If a Machinery Breakdown extension on the cold store equipment is not in place, the deterioration of stock cover often steps in as the substantive trigger because the proximate cause is still an insured peril. The cleaner structure is to hold both: Machinery Breakdown for the compressor itself and Deterioration of Stock for the affected vaccine inventory.

What Routes to the MB Policy Instead

The compressor itself, the bearing, the labour to replace it, and the recommissioning cost route to the Machinery Breakdown policy on the refrigeration plant. The post-event re-validation of the cold store (the qualification and verification work that the facility's quality unit needs to run before the chamber is returned to operational service) sits in a grey zone. Some insurers treat re-validation costs as part of the reasonable cost of putting the equipment back into service; others treat them as a regulatory compliance cost outside scope. Read the wording. Two claims with two sets of paperwork, frequently with different insurers, get filed for the same incident: the stock loss on one policy, the compressor repair on another. The reporting party (the facility) needs to lodge both promptly and keep them linked in correspondence.

The GDP, PIC/S, and NPRA Layer

In parallel with the insurance routing, the facility runs the GDP excursion procedure. The corrective and preventive action (CAPA) framework expects a root cause analysis, a corrective step (fix the compressor, validate the repair), and a preventive step (revisit the maintenance schedule, redundancy of refrigeration, alarm thresholds, contractor response time). Where the product class triggers NPRA reporting requirements, the facility's regulatory affairs team handles the notification; specific reporting timelines and scope depend on the product class and the facility's NPRA-registered procedures. The insurance claim and the regulatory file are separate workflows but draw on the same evidence: continuous temperature logs, alarm event records, contractor service reports, and the quality assurance disposition decision.

Where the Claim Gets Argued

Most disputes here turn on four issues. First, was the failure sudden and accidental or the result of a maintenance issue that had been observable beforehand? A surveyor will inspect the maintenance log on the refrigeration plant. Missing or incomplete maintenance records weaken the claim, and they also weaken the GDP audit position separately. Second, what was the actual value of the stock and on what basis? A facility that has not refreshed its sum insured for pharma cold storage in two years may be under-declared, particularly where stock value has moved with product mix. Third, what does the stability data say about the excursion? Some products survive a four-hour excursion at 11 degrees and remain saleable; others do not. The surveyor and the insurer will defer to the manufacturer's stability assessment and the facility's QA disposition. Fourth, is the alarm and monitoring record complete? A logger gap during the excursion is the single most common reason insurers reduce or deny pharma cold-chain claims.

Scenario 2: Temperature Excursion During an NPRA Inspection

What Actually Happens

The temperature excursion is caused by an interaction between the planned maintenance and a slower-than-expected switch-over to the back-up chiller. The inspection itself does not cause the excursion, but it does mean that the event is on the regulator's radar before the facility has completed its own internal incident response. The QA team applies the GDP excursion procedure to the affected API. Where stability data permits, lots are released back into manufacture; where it does not, the API is segregated. The CAPA file is opened on the same day and is part of what the NPRA inspector reviews before the inspection closes.

What the Deterioration of Stock Cover Does and Does Not Pay

This scenario is genuinely harder than the first. Whether the cover responds depends on the precise cause:

• If the back-up chiller failed to come online cleanly because of a hidden mechanical or electrical defect (a faulty contactor, a damaged sensor, a refrigerant issue), the cause is arguably machinery breakdown and the deterioration of stock cover typically responds.
• If the switch-over was simply slow because the maintenance procedure was poorly sequenced (engineer's operational decision), and the chiller equipment itself was not faulty, the cover may not respond because the proximate cause is operational rather than a peril.
• If the wording specifically excludes loss arising during routine maintenance or testing, the cover does not respond regardless of cause. Pharma cold-chain wordings often carry a maintenance and testing exclusion that is wider than the equivalent F&B wording.

The takeaway: routine maintenance windows are a known coverage soft-spot in pharma cold-chain wordings, and the overlap with an inspection makes the documentation trail more exposed than usual. Read the maintenance and testing exclusion in your wording carefully before relying on the cover during inspection windows. Plan inspections and maintenance to not overlap where possible.

The Off-Premises Power Failure Trigger

A separate but related cover that pharma buyers frequently confuse: off-premises power failure. Standard PIAM (Persatuan Insurans Am Malaysia) market convention typically applies a waiting period of around 24 hours before stock spoilage from an off-premises power failure (TNB outage, grid problem upstream of the facility) is treated as a covered loss. The 24-hour waiting period is a market convention, not a uniform rule; confirm your specific wording. The waiting period does not apply when the cause is an on-premises machinery breakdown; that routes through the MB and deterioration of stock pair. Many facilities assume off-premises power failure cover responds from minute one. It typically does not. Pharma facilities also routinely run validated back-up power on cold stores precisely because the waiting period sits well outside any product's permitted excursion window.

The GDP CAPA Workflow Alongside the Claim

The corrective and preventive action framework runs in parallel with the insurance claim. The CAPA file documents the root cause (whether the back-up chiller fault was equipment-driven or procedure-driven), the corrective action (repair, re-validate, retrain, or all three), and the preventive action (schedule changes, redundancy review, alarm threshold review). The same evidence pack supports the insurance submission. A clean CAPA file makes the claim conversation shorter, because the insurer is reading the facility's own root cause analysis rather than constructing one from interviews.

Scenario 3: Cold-Chain Breach in Pharma Distribution

What Actually Happens

Once the stock leaves the factory gate and is on the truck under the logistics provider's care, the deterioration of stock cover on the manufacturer's property policy no longer responds. The cover for stock in motion is the Marine Cargo policy (typical for road, sea, and multi-modal pharma consignments) or the Goods in Transit policy, whichever has been arranged for the consignment. Pharma cold-chain consignments are increasingly placed on Marine Cargo with a cold-chain endorsement that addresses the temperature warranty, the data logger requirement, and the GDP-aligned packaging specification.

Who Carries the Risk and Who the Insurance

Three legitimate structures exist for in-transit cold-chain consignments:

• Logistics provider carries cover. The contract specifies that the carrier holds the insurance during transport. Recovery flows through the carrier's policy. For pharma cargo, the carrier's cover often carries low per-incident sub-limits relative to consignment value.
• Shipper carries own Marine Cargo or Goods in Transit cover. The manufacturer holds its own policy with a cold-chain endorsement and a data logger warranty. This is the most common structure for valuable pharma consignments.
• Consignee carries cover. Where Incoterms or contract terms transfer risk to the buyer at the factory gate, the buyer's policy responds. Less common in domestic Malaysian pharma distribution.

The wrong assumption (that "someone has it covered") only surfaces when the claim is lodged and three parties point at each other. Define the cover structure in writing at the contract stage, not at the claim stage. For pharma cargo, the GDP framework also expects the shipper to verify the carrier's cold-chain capability and cover; this verification should happen before dispatch, not after the breach.

Cold-Chain Endorsement Specifics

In-transit pharma cold-chain cover commonly carries an endorsement and warranty package that addresses:

• Temperature warranty: the chamber is maintained within a specified range (commonly 2 to 8 degrees for chilled pharma) throughout the journey.
• Data logger requirement: a calibrated, validated temperature logger accompanies the consignment, with no gap in the log.
• Packaging warranty: the validated thermal packaging (qualified shipping container with phase-change materials, or active reefer with redundant power) is used as specified.
• Reefer maintenance and pre-trip inspection: the reefer unit has been serviced and pre-trip-inspected, with a record on file.
• Prompt notification: the shipper is notified of any excursion within a specified window, typically immediately on detection.

Three claim outcomes depend on the logger data:

• Logger shows continuous in-spec temperature: usually no claim because the product remains saleable.
• Logger shows a clear excursion at a discrete point with a known cause (generator failure): claim is usually straightforward subject to warranty compliance.
• Logger shows excursion but cause is ambiguous or logger gap: claim is contested, often denied citing warranty breach.

The discipline that protects the in-transit cover is the same as the discipline that protects the GDP audit: continuous data logging, calibrated equipment, intact records, prompt notification to the carrier and the insurer the moment the excursion is identified. For background on the underlying compliance framework, see Foundation's note on GMP compliance for pharmaceutical manufacturing in Malaysia; the GDP cold-chain discipline sits adjacent to GMP and uses many of the same controls.

Putting the Three Scenarios on One Page

Scenario	Proximate Cause	Primary Cover	Typical Trigger or Waiting Period
Vaccine cold store compressor failure overnight	Machinery breakdown of refrigeration plant	Deterioration of stock extension (for the stock loss); Machinery Breakdown (for the compressor)	Sudden and accidental breakdown; no waiting period typically; pharma cold-chain endorsement may apply
Excursion during NPRA inspection with chiller maintenance	Depends on whether back-up chiller fault or operational	Deterioration of stock if back-up chiller fault; possibly no cover if procedural; maintenance and testing exclusion may bite	Insured peril required; check maintenance and testing exclusion wording
Cold-chain breach in pharma distribution	Reefer generator failure during transport	Marine Cargo or Goods in Transit policy with cold-chain endorsement (whoever holds it)	Temperature warranty, data logger warranty, prompt notification
Off-premises power failure (TNB outage)	Upstream grid event	Deterioration of stock with off-premises power failure trigger	Waiting period commonly around 24 hours (PIAM convention); confirm wording

What to Check in Your Pharma Policy

1. Deterioration of stock sub-limit. Confirm the sum insured for stock under validated refrigeration matches the realistic peak stock value, not a stale historical figure. Pharma stock value can move materially with product mix.
2. Cause-of-loss wording. Read which perils trigger the cover. Machinery breakdown of refrigeration plant should be specifically included.
3. Machinery Breakdown extension on the cold store. Confirm whether the cold store compressor, condenser, evaporator, and control system are scheduled under the MB extension and at what sums insured.
4. Off-premises power failure waiting period. Confirm the waiting period (commonly around 24 hours under PIAM convention; confirm your specific wording) and whether your operational protection (validated back-up generator, switch-over procedure) is realistic against that waiting period. For most pharma products the waiting period sits well outside the product's permitted excursion window, so back-up power is essentially mandatory.
5. Maintenance and testing exclusion. Pharma wordings often carry a wider maintenance and testing exclusion than F&B wordings. Read it carefully and align your maintenance procedure to reduce reliance on cover during inspection or maintenance windows.
6. Data logger requirements. Confirm whether the wording requires continuous logging, what evidence the insurer expects at claim time, and whether the logger has to be calibrated and qualified under your facility's procedures.
7. GDP and PIC/S compliance warranties. Some pharma cold-chain wordings carry an explicit warranty that the facility operates to GDP and to PIC/S-aligned standards. A warranty breach can jeopardise the entire claim, not just the affected lot.
8. In-transit cold-chain endorsement. Confirm the temperature warranty, the data logger warranty, the packaging warranty, and the notification window in your Marine Cargo or Goods in Transit cover.
9. Re-validation costs after equipment repair. Confirm whether the wording covers the reasonable cost of post-repair re-validation of the cold store, or whether this falls into the regulatory cost category.
10. Responsibility split in distribution. Map who holds the cover at every point in the cold chain. Document this in the carrier contract and the customer contract, not just informally.

Frequently Asked Questions

Foundation's View

Foundation is a specialist intermediary, and pharma cold storage stock claims are one of the areas where the routing logic does most of the work and the GDP overlay does the rest. The three scenarios in this article are illustrative, but the underlying discipline is universal across Malaysian pharma facilities: know which policy responds to which cause of failure, keep continuous temperature records and a clean CAPA file, refresh the sub-limit at renewal against realistic peak stock value, and map the in-transit responsibility split in writing before any incident occurs. If you have not walked these scenarios through your own current cover, the next renewal is the natural moment to do so. The sibling F&B view is in cold storage stock claims for F&B factories; the routing logic is the same, but the regulatory overlay is lighter on the F&B side.